Abstract
Comments on the fast track guidance from the U.S. Food and Drug Administration on the treatment of cancer, as of January 2002. Significance of fast track applications to the treatment of cancer; Details of the guidance; Factors that contribute to the fast track approval of a drug; Pros and cons of the fast track development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
